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Abstract Haematopoiesis is the term used to describe the pro-
duction of blood cells. This is a tightly regulated hierarchical
system in which mature circulating blood cells develop from a
small population of haematopoietic stem (HSC) and progenitor
cells within the microenvironment of the bone marrow.
Molecular and genetic abnormalities arising in these stem cells
lead to a block in the normal programme of proliferation and
differentiation and result in the development of the blood cancers
known as the leukaemias and lymphomas. Recently the regula-
tory role of the bone marrow microenvironment or niche
has also become increasingly recognised. The interface
between the bone and bone marrow (endosteum) and
the region surrounding the blood vessels (perivascular)
provide distinct niches harbouring quiescent HSC or
proliferative HSC respectively. Current chemotherapeutic
regimes can often successfully target the proliferative
HSC but disease relapse occurs due to residual quies-
cent HSC. Understanding these developmental and reg-
ulatory processes and the associated cell communication
mechanisms are thus crucial to the development of new
treatment strategies. The CCN family of proteins have
been recognised to play a key role in all aspects of
haematopoiesis.
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Normal blood cell development
Bone marrow microenvironment
Normal adult blood cell production (haematopoiesis) takes
place mainly within the bone marrow. It is now acknowledged
that this microenvironment plays a key role in maintaining the
balance between proliferation and differentiation (Morrison
and Scadden 2014; Anthony and Link 2014). Specific regions
or niches within the marrow are associated with distinct stem
cell populations and this in turn is due to the stromal cell
populations present and the regulatory molecules which they
produce. The earliest stem cells, known as quiescent cells, are
generally found at the interface between the bone and bone
marrow or endosteal region. In contrast, the more proliferative
stem cells are usually found in the perivascular region (Ho
et al. 2015a). Matricellular proteins, including CCN family
members, play a key regulatory role in the bone marrow mi-
croenvironment (McCallum and Irvine 2009; Cheung et al.
2014; Johnson et al. 2014a) (Fig. 1).
Stem and progenitor cells
Haematologists have been interested in characterising the de-
velopmental stages of blood cell production for many years.
Early work focussed on the use of clonogenic assays and the
terminology derived from this still persists today (Ho et al.
2015). The prefix CFU denotes colony forming unit and the
suffix (G: granulocyte, M: macrophage, E: erythroid, MEG:
megakaryocyte) distinguishes the lineage of the cells making
up the clone. Developments in immunological classification
and flow cytometry allowed us to categorise these progenitor
cells further and provided an opportunity to sort and work
with purer populations of cells. Knowledge of surface antigen
expression has facilitated further discrimination between stem
and progenitor cell populations (Ho et al. 2015). Our current
concept of haematopoiesis is that of a hierarchical structure in
which a small number of multipotent stem cells develop along
specific pathways and differentiate into the mature circulating
blood cells (Fig. 2).
The role of the CCN family of proteins in haematopoiesis
There are limited published studies on the role of CCN family
members in haematopoiesis and fewer still which have exam-
ined the specific role of the microenvironment. Studies with
mouse bone marrow (Cheung et al. 2014) have shown that
CCN2 is expressed by bone marrow stromal cells although it
was barely detectable in unfractionated cells per se. A chimae-
ric fetal liver transplant model and culture systems were used
to show that CCN2 promotes B cell lymphopoiesis in the
presence of IL-7. CCN3 expression has also been reported
in mouse bone marrow both in the endosteal region near the
epiphysis and between the trabecular bone and microvascula-
ture. It was suggested that these CCN3 expressing cells rep-
resented both haematopoietic and stromal cell populations
(Katsube et al. 2009).
It is difficult to obtain normal bone marrow for research
studies and if one fractionates the sub-populations of stem and
progenitor cells there are very few cells to work with. There
are thus few publications in this area. BloodSpot is a publical-
ly available database of mRNA from a number of curated data
sets encompassing expression profiles in normal and malig-
nant haematopoiesis (Bagger et al. 2013; Bagger et al. 2012;
Bagger et al. 2016). The expression profile of CCN family
members was analysed in the Differentiation Map (DMAP)
data set which is comprised of purified populations of
haematopoietic stem cells, multiple progenitor cells and ma-
ture differentiated blood cells (211 samples). Expression of
CCN1, CCN2, CCN4 and CCN5 remained largely constant
across the different cell populations. CCN3 and CCN6 follow-
ed similar patterns of expression and were observed to be
expressed most highly in progenitor and mature cells of the
myeloid lineage (with the exception of granulocytes), suggest-
ing an association of these CCN members with myeloid dif-
ferentiation. None of this data has yet been validated at the
protein level (Fig. 3).
Most reports of CCN expression use enriched rather than
pure populations of cells and data generated must be
interpreted in the appropriate context. Similarly, the limited
number of cells obtainable for study mean that most investi-
gators focus on the role of a single CCN family member and
mechanistic studies are only available in malignant patholo-
gies where there are good cell line models available. CCN2
and CCN3 are the only family members which have been
studied extensively in normal haematopoiesis.
Fig. 1 The Bone Marrow Microenvironment. The marrow
microenvironment consists of two distinct niches: the endosteal
compartment which harbours quiescent stem cells and the region
surrounding the blood vessels, peri-vascular, which harbours
proliferative stem cells
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CCN2 expression in normal cells has been studied in both
the adult and paediatric setting. CCN2 was found to be nega-
tive by PCR in mononuclear cells from 120 children (age 1.8–
15.8 years) with insulin-dependent diabetes mellitus (IDDM)
and CD34+ cells from 100 cord blood samples (Vorwerk et al.
2000). Similarly, more recent investigations of adult mononu-
clear cells from normal bone marrow (10 samples), peripheral
blood (10 samples) and CD34+ enriched cells from bone mar-
row (7 samples) or peripheral blood (9 samples) confirmed
this lack of expression using microarrays and quantitative
PCR (Sala-Torra et al. 2007).
CCN3 expression has been studied in normal human adult
bone marrow and peripheral blood (McCallum et al. 2006) as
well as cord blood (Gupta et al. 2007). In adults we detected
CCN3 at all stages of development within the myeloid line-
age; CD34+ progenitors, mononuclear cells (MNC) and neu-
trophils derived from normal bone marrow (NBM) and nor-
mal peripheral blood (nPB). We found the highest expression
in CD34+ progenitors and MNC cells whilst expression was
lower in mature neutrophils.
Human cord blood (CB) is also a recognised source of
haematopoietic progenitor cells although these cells differ
subtly from those found in bone marrow (Moretta et al.
2016; Notta et al. 2016). These disparities may be a reflection
of the contrast in microenvironment in which CB stem cells
develop (Stojko et al. 2016; Beksac 2016). Gupta et al. (Gupta
et al. 2007) isolated primitive progenitors from human cord
blood and found that, in contrast to the adult setting, CCN3
expression was restricted to the CD34+ progenitor cell popu-
lation. They then used a CCN3 knockdown strategy to show
that CCN3 was required to maintain long term culture initiat-
ing cell (LTC-IC) cultures, the most primitive haematopoietic
progenitors; colony forming capacity of less primitive
progenitors was enhanced by this strategy, but these progeni-
tors failed to generate secondary colonies. The CCN3 knock-
down cells had reduced Hes1 activity and a diminished re-
sponse to Jagged1, consistent with reported links between
CCN3 and the Notch signaling pathway (Suresh and Irvine
2015). These findings suggest that CCN3 is required for self-
renewal and distinguishes alterations in response to CCN3
within subpopulations of primitive stem cells. It also high-
lights the importance of CCN3 and Notch relationship within
haematopoietic development.
Studies in mice have shown that CCN3 regulates long term
repopulating activity of HSCs through binding to integrin
αvβ3 (Ishihara et al. 2014). Thrombopoietin (TPO) mediates
this integrin binding and also stimulates the expression of
CCN3 in HSCs. In contrast, stem cell factor (SCF) co-
cultured with CCN3 had no effect on HSC function and
inhibited expression of CCN3. This study establishes that
CCN3 expression in HSCs is strongly influenced by cytokine
stimulation and this in turn is a reflection of the microenviron-
ment in which the cells live.
Further evidence for the role of cytokines in CCN3 regula-
tion comes from the work of Kimura (Kimura et al. 2010).
They used a microarray approach to look for target genes of
STAT5A/B activated by cytokines in murine HSCs and pro-
genitors. They showed that IL-3 induced binding of STAT5A/
B to a γ-interferon activated sequence site in the CCN3 gene
promoter region. This paper provides additional confirmation
that CCN3 is a cytokine inducible gene and demonstrates that
it is a direct target of STAT5A/B. The STAT signalling path-
way plays a key role in haematopoiesis and it is widely report-
ed as being implicated in a wide range of haematological
neoplasms, particularly those of myeloid origin (Chougule
et al. 2016; Balligand et al. 2016; Koschmieder et al. 2016;
Fig. 2 Haematopoiesis.
Haematopoiesis is a hierarchical
structure in which a small number
of stem cells go through a
programme of proliferation and
differentiation to produce the
mature cells which circulate in the
blood stream. The different stem
cell populations may be named on
the basis of the functional
clonogenic assays in which they
were first described (left hand side
of diagram) or by their surface
antigen expression (right hand
side of diagram)
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Miltiades et al. 2016; Muller et al. 2016; Wang and Bunting
2016; Xu et al. 2016).
Blood cancers
CCN1 and multiple myeloma
Multiple myeloma (MM) is characterised by the accumulation
of malignant plasma cells in the bone marrow (BM) leading to
the overproduction ofmonoclonal immunoglobulins, osteolytic
bone lesions, renal disease and immunodeficiency. MM is usu-
ally preceded by the premalignant conditions monoclonal
gammopathy of undetermined significance (MGUS) and/or
smouldering multiple myeloma (SMM). Interactions between
MM cells and the BM microenvironment are well-established
to play a role in supporting the growth and survival of MM
cells, as well as enhancing bone resorption through increased
osteoclast activity and suppression of osteoblast activity
(Kawano et al. 2015).
CCN1 is known to play a role in bone remodelling, primar-
ily through stimulation of osteoblast differentiation (Kawaki
et al. 2011) and inhibition of osteoclastogenesis (Crockett
et al. 2007) and this has led a number of groups to investigate
its role in MM. Two studies have recently reported that mes-
enchymal cells in the BM microenvironment of MM patients
express CCN1 (Dotterweich et al. 2014; Johnson et al. 2014).
Dotterwich and colleagues (Dotterweich et al. 2014) reported
that co-culture of a MM cell line with primary mesenchymal
cells from healthy donors promotes splicing, transcription and
expression of CCN1 in MM cells. They further showed that
exogenous CCN1 enhanced survival of a MM cell line and
Fig. 3 CCN expression in
normal haematopoiesis. CCN3
and CCN6 gene expression in
enriched populations of
haematopoeitic cells (Data from
GSE24759). HSC –
haematopoietic stem cell; CMP –
common myeloid progenitor;
GMP – granulocyte-monocyte
progenitor; MEP –
megakaryocyte-erythroid
progenitor; CFU-Mono –
monocyte colony forming units;
CFU-G – granulocyte colony
forming units; CFU-Meg –
megakaryocyte colony forming
units
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suggest that CCN1 may support MM cell viability and asso-
ciated bone disease.
In contrast to this, Johnson (Johnson et al. 2014) reported
that recombinant CCN1 decreased the growth of a MM cell
line at high concentrations and overexpression of CCN1 in
MM cells reduced tumour growth, inhibited osteoclastogene-
sis and stimulated osteoblastogenesis in a mouse model of
MM. Furthermore, the authors found that CCN1 levels in
the BMmicroenvironment could be a biomarker for MM pro-
gression. High levels of CCN1 in patients with MGUS or
SMM were found to be associated with a longer time to pro-
gression to active MM, and elevated levels of CCN1 in MM
patients in remission were associated with superior
progression-free and overall survival. This study suggests that
increasing CCN1 levels in the BM microenvironment may
offer an approach to delay the progression of MGUS/SMM
to active MM, as well as enhancing survival of patients with
active myeloma.
In support of this theory, Li (Li et al. 2012) reported that
intrabone injection of mesenchymal stem cells, expressing
high levels of bone remodelling proteins such as CCN1,
prevented MM-induced bone disease, promoted osteoblast
maturation, suppressed osteoclast formation and inhibited
MM cell growth in a preclinical model of MM. While the role
of CCN1 in MM is not yet fully unravelled, overall the evi-
dence to date suggests that CCN1 could provide a therapeutic
strategy for treating MM bone disease.
CCN1 and acute myeloid leukaemia
Acute Myeloid Leukaemia (AML) is a term used to represent
a group of leukaemias in which there is a block in differenti-
ation in the myeloid lineage of cells. These leukaemias are the
result of malignant transformation in haematopoietic stem or
progenitor cells and are characterised by the presence of 20 %
or more immature blast cells in the blood or bone marrow at
diagnosis. AML is classified into specific subtypes based on
cytogenetic and molecular characteristics defined by the
World Health Organisation. This classification provides prog-
nostic information regarding poor, intermediate and
favourable risk groups (Arber et al. 2016). It is therefore im-
portant in all studies of AML to know the relevant classifica-
tion of the patients being studied.
There have been reports of a role for CCN1 in both bone
marrowmicroenvironment and stem cells in AML. It has been
suggested that bone marrow stromal cells may play a role in
chemotherapy resistance. Studies with bone marrow stromal
cell lines showed high levels of expression of CCN1 and
knockdown of CCN1 using antibodies or RNAi led to in-
creased sensitivity to chemotherapy in AML-stromal cell co-
cultures (Long et al. 2015). Further investigations found that
CCN1 signalling was mediated by Spleen Tyrosine Kinase
(SYK) which acts downstream of CCN1 and contributes to
chemo-resistance. This work was carried out using NB4 and
THP1 cell lines which represent adult pro-myelocytic
(favourable risk) and pediatric monocytic (intermediate risk)
AML; details of the primary AML cells used were not given
(Long et al. 2015). It is therefore difficult to ascertain how
applicable these observations are to other AML subtypes.
The largest cohort of AML patients on which CCN1 ex-
pression data is available (500 patients) is from the MILE
(Microarray Innovations in LEukemia) study (Kohlmann
et al. 2008). This database contains over 500 AML samples
classified into 6 clinically recognised subtypes and identified
increased expression of CCN1 in two subgroups, t(8;21) and
complex karyotype, associated with favourable and
unfavourable risk, respectively; array data only is available
for this study. CCN1 protein expression has also been exam-
ined in a panel of leukaemia cell lines and found to be in-
creased in two AML cell lines representing a pediatric mye-
locytic (favourable risk) and adult monocytic (unfavourable
risk) AML. Knockdown of CCN1 using antibodies or siRNA
suppressed proliferation and increased apoptosis suggesting
that CCN1 was acting as a tumour promoter in AML
(Niu et al. 2014). Primary AML bone marrow cells
showed similarly increased levels of CCN1 although no
patient details were given and there was no apparent
association with risk group. Mechanistic studies demon-
strated that CCN1 acts through the MEK/ERK pathway
leading to upregulation of cMyc and Bcl-xL and down-
regulation of BAX (Niu et al. 2014).
CCN2 and acute lymphoblastic leukaemia
Acute Lymphoblastic Leukaemia (ALL) is the most common
leukaemia found in children but it is also found in adults
where it has a poor prognosis. Research in this field is fo-
cussed on finding new prognostic biomarkers and alternative
therapeutic targets (Arber et al. 2016; He et al. 2016).
CCN2 has been found to be overexpressed in both adult
and paediatric ALL compared to normal HSCs (Sala-Torra
et al. 2007; Vorwerk et al. 2000). A role for CCN2 as a tumour
marker was first reported by Vorwerk et al. who demonstrated
by RT-PCR that it was specifically expressed in malignant
lymphoblasts in childhood ALL (Vorwerk et al. 2000).
Further work using quantitative PCR and microarrays con-
firmed high CCN2 expression in lymphoblasts in adult ALL
and allowed discrimination from Acute Myeloid Leukaemia
(AML)(Sala-Torra et al. 2007). Hypo-methylation of the
CCN2 gene locus has been demonstrated to be a common
feature in paediatric ALL and it has been suggested that it is
a necessary but not sufficient pre-requisite for its deregulated
transcription (Welch et al. 2013).
It has been shown that CCN2 expression is associated with
poor prognosis (Sala-Torra et al. 2007; Wells et al. 2016).
Quantitative PCR carried out on 79 adult ALL cases found
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CCN2 expression was associated with unfavourable cytoge-
netics and a worse overall survival (Sala-Torra et al. 2007).
Pre-clinical studies with ALL cell lines and mouse models
found that in vitro knock down of CCN2 or treatment with
anti-CCN2 antibody could prolong survival (Lu et al. 2014).
Recent workwithmice has elucidated the potential underlying
mechanism for this effect. Injection of NOD/SCID mice with
high or low CCN2- expressing cells found that elevated
levels led to reduced survival and that CCN2 had affect-
ed the bone marrow microenvironment causing increased
extra-cellular matrix deposition (Wells et al. 2016).
Together these studies suggest that CCN2 may provide
a novel therapeutic target in ALL.
CCN2 and lymphoma
The Lymphomas are a group of blood cancers in which ma-
lignant lymphocytes accumulate in the lymph nodes causing
characteristic swelling referred to as lymphadenopathy.
Occasionally the malignant cells spill into the blood and the
disease enters what is referred to as a ‘leukaemic phase’. In
these disorders the relevant microenvironment is essentially
the lymph node (Burger et al. 2009). There are two major sub-
divisions of lymphoma called Hodgkins and non-Hodgkins
based on the presence or absence of Reed Sternberg cells, a
type of neoplastic B cell. Hodgkins disease generally has a
good prognosis whereas the non-Hodgkins lymphomas en-
compass a diverse group of disorders with poorer outcome.
Gene expression studies carried out on patients with large
B-cell lymphoma, a non-Hodgkins lymphoma, identified an
expression signature associated with good prognostic out-
come (Lenz et al. 2008). The authors found that stromal cells
expressing genes encoding components of the extracellular
matrix, including CCN2, were found in patients with im-
proved survival. Their findings support the importance of
targeting the microenvironment for improved therapeutic effi-
cacy (Burger et al. 2009).
CCN2 has been shown to be highly expressed in cells from
patients with Hodgkins (44 patients) compared to non-
Hodgkins (32 patients) lymphoma (Birgersdotter et al.
2010). Increased expression was demonstrated at both the
RNA and protein level and it was suggested that this was
associated with the high incidence of fibrosis in these patients.
Elevated CCN2 expression has also been demonstrated in
cells from patients with peripheral T cell lymphoma, not oth-
erwise specified, compared to normal peripheral blood Tcells.
In this case data was reported from microarray analysis and
not further validated (Mahadevan et al. 2005).
CCN3 and chronic myeloid leukaemia
Chronic Myeloid Leukaemia (CML) is the only blood cancer
which is characterised by a single specific genetic marker, the
Philadelphia chromosome. This is caused by a reciprocal
translocation between chromosomes 9 and 22 and leads to
the formation of the bcr-abl fusion protein associated with
elevated tyrosine kinase activity. Tyrosine kinase inhibitors
have been developed as targeted therapy for CML and have
been successful in obtaining long term remissions in patients.
Nevertheless, many patients become resistant to these inhibi-
tors and it is acknowledged that the leukaemia initiating cell
remains. Efforts are now being made to find targets other than
the kinase activity and to understand the relationship of the
leukaemic stem cell with the surrounding microenvironment
(Hughes and Ross 2016).
CCN3 expression is dys-regulated at both the RNA and
protein level in CML and there is a reciprocal relationship
between CCN3 and BCR-ABL expression (McCallum et al.
2006). A comparison of CCN3 gene expression from purified
stem and progenitor cells from CML patients in different
Fig. 4 CCN3 expression in
CML. CCN3 expression in
megakaryocyte-erythroid (MEP)
enriched cells from normal
donors (N) and CML patients in
chronic phase (CP), acute phase
(AP) or blast crisis (BC). Data
from GSE47927
202 Crawford L.J., Irvine A.E.
stages of disease (12 samples) and normal volunteers (3 sam-
ples) demonstrated that there are significantly lower levels of
CCN3 in megakaryocyte-erythroid progenitor (MEP) cells
from CML patients compared to healthy counterparts
(Cramer-Morales et al. 2013). Figure 4 we used a multi-
potent haemopoietic cell line, FDCP-MIX, expressing BCR-
ABL kinase to investigate the effects of the kinase in early
haemopoietic stem cells. CCN3 was found to be downregu-
lated and tyrosine phosphorylated as a consequence of BCR-
ABL kinase activity in these cells. Human CML cell lines and
primary cells from patients also expressed low or undetectable
levels of CCN3. Treatment in vitro with the tyrosine kinase
inhibitor imatinib decreased BCR-ABL kinase activity and
increased CCN3. The latter observations were validated by
clinical studies in which patients treated with imatinib showed
a return to normal levels of CCN3 expression when they
responded to treatment (McCallum et al. 2006).
The mechanism of action of CCN3-induced growth regu-
lation has been investigated using a number of cell line
models. In the FDCP-MIX CML cell line model it was shown
that BCR-ABL kinase activity not only regulates transcrip-
tional activity but also enhances CCN3 secretion by the cells
(McCallum et al. 2006). Overexpression of CCN3 in a human
CML cell line resulted in a reduction in clonogenicity, in-
crease in apoptosis and reduction in phosphorylation of Erk2
(McCallum et al. 2012). This is consistent with previous re-
ports of tumour cell survival being impacted by the Erk1/2
pathway (Balmanno and Cook 2009).
CCN3 is a non-canonical NOTCH ligand which is known
to be a core signalling pathway in the haematopoietic system
(Bigas et al. 2012). In CML cells modified to overexpress
CCN3 or treated with exogenous recombinant CCN3 there
was a significant decrease in NOTCH1 signalling (Suresh
et al. 2013). Furthermore, silencing of BCR-ABL in a CML
cell line reduced full length NOTCH and inhibited cleavage of
the NOTCH intracellular domain leading to a decrease in
downstream effector molecules cMyc and Hes1 (Suresh
et al. 2013). This suggests that disruption of the NOTCH-
CCN3 pathway may contribute to the pathogenesis of CML
(Suresh and Irvine 2015).
Association of other CCN family members
with haematopoiesis and blood cancers
With the advent of high throughput technologies it is possible
to screen for expression of thousands of genes in both cell
lines and primary clinical material. CCN family members
are now included on many microarray platforms and informa-
tion on expression profiling is increasing exponentially. Two
large online datasets discussed in this review, BloodSpot and
MILE, are prime examples of information which suggests a
wider involvement of CCN family members in blood cancer
than currently appreciated but has not yet been validated
(Kohlmann et al. 2008; Bagger et al. 2016). For example, in
addition to the role of CCN1 in AML discussed above, the
MILE study shows that CCN2 expression is significantly de-
creased compared to normal cells in two cytogenetic subtypes
of AML (inv(16), t(15;17)) that are classified as belonging to a
more favourable risk group. CCN3 displays a more variable
expression pattern in AML. It is found to be increased across
three different cytogenetic subtypes (normal karyotype, com-
plex karyotype and t(8;21)) all belonging to different risk
groups, and is observed to be decreased in AML patients with
MLL translocations (Kohlmann et al. 2008). None of these
observations have been followed up with protein and mecha-
nistic investigations.
This review has focused on the role of CCN members in
haematological malignancies where there is more than simply
basic expression data available. The haematology research
community is currently focusing on targeting the microenvi-
ronment in addition to the malignant stem cell to improve
therapeutic efficacy. It is clear the CCN family will play a
key part in these future developments.
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